[
  {
    "ts": null,
    "headline": "Incyte : MPN Data Highlights from EHA 2025",
    "summary": "MPN Data Highlights from EHA 2025 June 15, 2025 ...",
    "url": "https://finnhub.io/api/news?id=966247a453fd08580bed53804e09893d32b19a83cf9c33c8593aa156d7f4aae0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749984543,
      "headline": "Incyte : MPN Data Highlights from EHA 2025",
      "id": 135285458,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "MPN Data Highlights from EHA 2025 June 15, 2025 ...",
      "url": "https://finnhub.io/api/news?id=966247a453fd08580bed53804e09893d32b19a83cf9c33c8593aa156d7f4aae0"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]",
    "url": "https://finnhub.io/api/news?id=29208eea90e727742476381adcc0aad54ad945d14d3ae868b652342fdc50552f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749980967,
      "headline": "Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches",
      "id": 135284982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]",
      "url": "https://finnhub.io/api/news?id=29208eea90e727742476381adcc0aad54ad945d14d3ae868b652342fdc50552f"
    }
  },
  {
    "ts": null,
    "headline": "QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)",
    "summary": "VENLO, Netherlands & WILMINGTON, Del., June 15, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibro",
    "url": "https://finnhub.io/api/news?id=8d07792e9f0ac1456280a0afd2f2a40d1ed97999a0e8b2566aaaa5e407603033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749974400,
      "headline": "QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)",
      "id": 135284983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "VENLO, Netherlands & WILMINGTON, Del., June 15, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibro",
      "url": "https://finnhub.io/api/news?id=8d07792e9f0ac1456280a0afd2f2a40d1ed97999a0e8b2566aaaa5e407603033"
    }
  },
  {
    "ts": null,
    "headline": "Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
    "summary": "WILMINGTON, Del., June 15, 2025--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
    "url": "https://finnhub.io/api/news?id=61d4060fd748dfba15f614594fb59deab26bf4cfc99982783d3474b7fa7b6748",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749971700,
      "headline": "Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
      "id": 135284984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., June 15, 2025--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025",
      "url": "https://finnhub.io/api/news?id=61d4060fd748dfba15f614594fb59deab26bf4cfc99982783d3474b7fa7b6748"
    }
  },
  {
    "ts": null,
    "headline": "Qiagen & Incyte Announce Precision Medicine Collaboration To Develop Companion Diagnostics For Patients With Mutant Calr-Expressing Myeloproliferative Neoplasms",
    "summary": "Incyte Corp: * QIAGEN AND INCYTE ANNOUNCE PRECISION MEDICINECOLLABORATION TODEVELOP COMPANION DIAGNOSTICS FOR PATIENTS WITH MUTANTCALR-EXPRESSING MYELOPROLIFERATIVE NEOPLASMS ...",
    "url": "https://finnhub.io/api/news?id=8f33c9324365926959f034ddd5859143e62a34ef957d40799a05d6e7136b77f6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749960548,
      "headline": "Qiagen & Incyte Announce Precision Medicine Collaboration To Develop Companion Diagnostics For Patients With Mutant Calr-Expressing Myeloproliferative Neoplasms",
      "id": 135280784,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Incyte Corp: * QIAGEN AND INCYTE ANNOUNCE PRECISION MEDICINECOLLABORATION TODEVELOP COMPANION DIAGNOSTICS FOR PATIENTS WITH MUTANTCALR-EXPRESSING MYELOPROLIFERATIVE NEOPLASMS ...",
      "url": "https://finnhub.io/api/news?id=8f33c9324365926959f034ddd5859143e62a34ef957d40799a05d6e7136b77f6"
    }
  },
  {
    "ts": null,
    "headline": "Positive Late-Breaking Data For Incyte's First-In-Class Mutcalr-Targeted Therapy Inca033989 In Essential Thrombocythemia Presented At Eha2025",
    "summary": "Incyte Corp: * POSITIVE LATE-BREAKING DATA FOR INCYTE’S FIRST-IN-CLASSMUTCALR-TARGETED THERAPY INCA033989 IN ESSENTIAL THROMBOCYTHEMIAPRESENTED AT EHA2025 * INCYTE CORP...",
    "url": "https://finnhub.io/api/news?id=404e109039252b06df1f2f2ce7f0879dd6beca7a010ac8f6b627bb0b8d8b0822",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749957491,
      "headline": "Positive Late-Breaking Data For Incyte's First-In-Class Mutcalr-Targeted Therapy Inca033989 In Essential Thrombocythemia Presented At Eha2025",
      "id": 135279127,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Incyte Corp: * POSITIVE LATE-BREAKING DATA FOR INCYTE’S FIRST-IN-CLASSMUTCALR-TARGETED THERAPY INCA033989 IN ESSENTIAL THROMBOCYTHEMIAPRESENTED AT EHA2025 * INCYTE CORP...",
      "url": "https://finnhub.io/api/news?id=404e109039252b06df1f2f2ce7f0879dd6beca7a010ac8f6b627bb0b8d8b0822"
    }
  }
]